ETBX-011
- Generic Name
- ETBX-011
- Drug Type
- Biotech
- Unique Ingredient Identifier
- RP9RQ0SOM8
- Background
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy
Phase 1
Withdrawn
- Conditions
- Melanoma
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03167177
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath